Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Response To Brexit Creates Inconsistences In Remaining Internal Market, Industry Warns

Executive Summary

MedTech Europe is calling for European-wide action on continued availability of medical devices in the immediate aftermath of Brexit as countries divide, and statistics demonstrate potentially major health threats ahead.

You may also be interested in...



Commission Disregards EU Industry Brexit Pleas And Tells EU Medtech To ‘Get On With It’

The European Commission rejects MedTech Europe’s warnings over the impact of a no-deal Brexit on future availability of medical devices and tells industry that while a no-deal Brexit is still a possibility, Brussels has issued enough advice for industry to get its house in order now.

Europe's Electromedical Industry Calls On EU To Recognize UK Certificates After No-Deal Brexit

While the UK says it will continue to recognize EU27-issued certificates for medical devices in the event of a no-deal Brexit, the EU has not offered to reciprocate. European imaging, health IT and electromedical manufacturers are now pressuring the European Commission to set up limited transition arrangements.

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel